跳至主要内容
临床试验/NCT04746989
NCT04746989进行中(未招募)不适用

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Probenecid vs Allopurinol

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 294,878 人开始时间: 2021年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
294,878
试验地点
1
主要终点
Time to dementia onset

研究概览

简要总结

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

详细描述

This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) intramural research program. This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • No prior use of urate-lowering agents, including probenecid and allopurinol anytime prior to cohort entry date
  • Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date

排除标准

  • Prior history of dementia measured anytime prior to cohort entry date
  • No prior history of gout recorded in the 365 days prior to cohort entry date
  • Prior history of nursing home admission in the 365 days prior to the cohort entry date

研究组 & 干预措施

Probenecid

Exposure group

干预措施: Probenecid (Drug)

Allopurinol

Reference group

干预措施: Allopurinol (Drug)

结局指标

主要结局

Time to dementia onset

时间窗: Through study completion (a median of 243 days)]

Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.

次要结局

  • Time to Alzheimer's disease onset(Through study completion (a median of 243 days)])

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rishi J. Desai

Assistant Professor

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验